Company Profile
IQV insider trades (13 months) →Today's multi-factor rank: 379 of 466 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
| Date | Open | High | Low | Close | Volume |
|---|
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Sentiment Metrics
Expected move
IQVIA Holdings Inc. (IQV) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| 8-K | 2026-09-09 | View filing ↗ |
| 8-K | 2026-07-28 | View filing ↗ |
| 8-K | 2026-06-11 | View filing ↗ |
| 8-K | 2026-06-04 | View filing ↗ |
| 8-K | 2026-06-03 | View filing ↗ |
| 8-K | 2026-05-07 | View filing ↗ |
| 8-K | 2026-05-05 | View filing ↗ |
| 8-K | 2026-04-23 | View filing ↗ |
| ARS | 2026-02-27 | View filing ↗ |
| 10-K | 2026-02-17 | View filing ↗ |
Company and Executive Profile
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Mr. Ari Bousbib | CEO & Chairman | 64 | 7.16M |
| Mr. Eric M. Sherbet J.D. | Executive VP, General Counsel & Secretary | 61 | 1.50M |
| Mr. W. Richard Staub III | President of Research & Development Solutions | 62 | 1.83M |
| Mr. Alistair Grenfell | President of Commercial Solutions | 51 | 1.70M |
| Mr. Michael J. Fedock MBA | Executive VP & Chief Financial Officer | 49 | - |
| Mr. James G. Berkshire | Executive Vice President of Global Infrastructure & Operations | 51 | - |
| Ms. Keriann Cherofsky | Senior VP, Corporate Controller & Chief Accounting Officer | 40 | - |
| Dr. Jeffrey A. Spaeder M.D. | Chief Medical & Scientific Officer | - | - |
You have seen the engine room
Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.